Advertisement

Plasma Adiponectin Concentration Is Associated With Skeletal Muscle Insulin Receptor Tyrosine Phosphorylation, and Low Plasma Concentration Precedes a Decrease in Whole-Body Insulin Sensitivity in Humans

  1. Norbert Stefan1,
  2. Barbora Vozarova1,
  3. Tohru Funahashi2,
  4. Yuji Matsuzawa2,
  5. Christian Weyer1,
  6. Robert S. Lindsay1,
  7. Jack F. Youngren3,
  8. Peter J. Havel4,
  9. Richard E. Pratley1,
  10. Clifton Bogardus1 and
  11. P. Antonio Tataranni1
  1. 1Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona
  2. 2Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan
  3. 3Department of Medicine, Division of Diabetes and Endocrine Research, Mount Zion Medical Center, University of California, San Francisco, California
  4. 4Department of Nutrition, University of California, Davis, California

    Abstract

    Adiponectin, the most abundant adipose-specific protein, has been found to be negatively associated with degree of adiposity and positively associated with insulin sensitivity in Pima Indians and other populations. Moreover, adiponectin administration to rodents has been shown to increase insulin-induced tyrosine phosphorylation of the insulin receptor (IR) and also increase whole-body insulin sensitivity. To further characterize the relationship between plasma adiponectin concentration and insulin sensitivity in humans, we examined 1) the cross-sectional association between plasma adiponectin concentration and skeletal muscle IR tyrosine phosphorylation and 2) the prospective effect of plasma adiponectin concentration at baseline on change in insulin sensitivity. Fasting plasma adiponectin concentration, body composition (hydrodensitometry or dual energy X-ray absorptiometry), insulin sensitivity (insulin-stimulated glucose disposal, hyperinsulinemic clamp), and glucose tolerance (75-g oral glucose tolerance test) were measured in 55 Pima Indians (47 men and 8 women, aged 31 ± 8 years, body fat 29 ± 8% [mean ± SD]; 50 with normal glucose tolerance, 3 with impaired glucose tolerance, and 2 with diabetes). Group 1 (19 subjects) underwent skeletal muscle biopsies for the measurement of basal and insulin-stimulated tyrosine phosphorylation of the IR (stimulated by 100 nmol/l insulin). The fold increase after insulin stimulation was calculated as the ratio between maximal and basal phosphorylation. Group 2 (38 subjects) had follow-up measurements of insulin-stimulated glucose disposal. Cross-sectionally, plasma adiponectin concentration was positively associated with insulin-stimulated glucose disposal (r = 0.58, P < 0.0001) and negatively associated with percent body fat (r = −0.62, P < 0.0001) in the whole group. In group 1 plasma adiponectin was negatively associated with the basal (r = −0.65, P = 0.003) and positively associated with the fold increase in IR tyrosine phosphorylation (r = 0.69, P = 0.001) before and after the adjustment for percent body fat (r = −0.58, P = 0.01 and r = 0.54, P = 0.02, respectively). Longitudinally, after adjustment for age, sex, and percent body fat, low plasma adiponectin concentration at baseline was associated with a decrease in insulin sensitivity (P = 0.04). In conclusion, our cross-sectional data suggest a role of physiological concentration of fasting plasma adiponectin in the regulation of skeletal muscle IR tyrosine phosphorylation. Prospectively, low plasma adiponectin concentration at baseline precedes a decrease in insulin sensitivity. Our data indicate that adiponectin plays an important role in regulation of insulin sensitivity in humans.

    Footnotes

    • Address correspondence and reprint requests to Norbert Stefan, Clinical Diabetes and Nutrition Section, National Institutes of Health, 4212 N. 16th St., Rm. 5-41, Phoenix, AZ 85016. E-mail: nstefan{at}mail.nih.gov.

      Received for publication 19 January 2002 and accepted in revised form 6 March 2002.

      N.S. and B.V. contributed equally to this work.

      T.F. and Y.M. were supported by the Japan Society for the Promotion of Science and Education (JSP-RFTF 97L00801) and a grant from the Fuji Foundation for Protein Research.

      ELISA, enzyme-linked immunosorbent assay; EMBS, estimated metabolic body size (fat – free mass + 17.7 kg); IR, insulin receptor; IRS-1, IR substrate-1; OGTT, oral glucose tolerance test.

    | Table of Contents
    Advertisement